365546-04-9

Upstream product

• 294-90-6 1,4,7,10-tetraazacyclododecan 
• 18880-00-7 1-(bromomethyl)-4-(1,1-dimethylethyl)benzene 
• 162148-45-0 1,4,7,10-tetraaza-cyclododecane-1,7-dicarboxylic acid dibenzyl ester 
• 824401-45-8 1,7-bis(benzyloxycarbonyl)-4,10-bis(4-tert-butylbenzyl)-1,4,7,10-tetraazacyclododecane 

Downstream Products

• 824401-47-0 1,7-bis(tert-butyoxycarbonylmethyl)-4,10-bis(4-(tert-butyl)benzyl)-1,4,7,10-tetraazacyclododecane 
• 366497-39-4 copper-1,7-(4-tert-butylphenylmethyl)cyclen 

Relevant academic research and scientific papers

Comparative in vivo behavior studies of cyclen-based copper-64 complexes: Regioselective synthesis, X-ray structure, radiochemistry, log P, and biodistribution

The in vivo behavior of copper(II)-cyclen complexes was modified via substitution of the parent ligand with two different substituents, 4-tert-butylbenzyl and acetate. This was achieved by using same synthetic strategy (regioselective protection/first alk

Regioselective N-substitution of cyclen with two different alkyl groups: Synthesis of all possible isomers

All possible configurations of two different groups on the four nitrogen atoms of cyclen were achieved using four differently protected cyclen intermediates including the novel mono-protected cyclen compound, mono-N-Cbz-cyclen.

β-Cyclodextrin dimers as potential tumor pretargeting agents

A β-cyclodextrin dimer binds a di-tert-butylbenzyl-Cucyclen with high affinity, demonstrating potential as a receptor/ligand system for tumor pretargeting with monoclonal antibodies.